{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:32:37Z","timestamp":1792096357857,"version":"4.4.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.vaccine.2019.11.058","type":"journal-article","created":{"date-parts":[[2019,12,7]],"date-time":"2019-12-07T00:26:14Z","timestamp":1575678374000},"page":"3489-3500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine"],"prefix":"10.1016","volume":"38","author":[{"given":"Fernanda","family":"Tavares-Da-Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maribel Miranda","family":"Co","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Dessart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Herv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"L\u00f3pez-Fauqued","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Mahaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Van Holle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Ulrich","family":"Stegmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.11.058_b0005","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.11.058_b0010","doi-asserted-by":"crossref","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2019.11.058_b0015","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1212\/WNL.0b013e3182a3516e","article-title":"The global epidemiology of herpes zoster","volume":"81","author":"Yawn","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2019.11.058_b0020","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","article-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction","volume":"82","author":"Yawn","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.vaccine.2019.11.058_b0025","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMcp1403062","article-title":"Clinical practice. Postherpetic neuralgia","volume":"371","author":"Johnson","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.11.058_b0030","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ophtha.2007.10.009","article-title":"Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity","volume":"115","author":"Liesegang","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.vaccine.2019.11.058_b0035","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.mayocp.2013.03.014","article-title":"Herpes zoster eye complications: rates and trends","volume":"88","author":"Yawn","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.vaccine.2019.11.058_b0040","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.ophtha.2016.03.005","article-title":"Epidemiology of herpes zoster ophthalmicus: recurrence and chronicity","volume":"123","author":"Tran","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.vaccine.2019.11.058_b0045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1741-7015-8-37","article-title":"The impact of herpes zoster and post-herpetic neuralgia on quality-of-life","volume":"8","author":"Johnson","year":"2010","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2019.11.058_b0050","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.11.058_b0055","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.11.058_b0060","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1016\/j.vaccine.2019.03.043","article-title":"Safety profile of the adjuvanted recombinant zoster vaccine: pooled analysis of two large randomised phase 3 trials","volume":"37","author":"Lopez-Fauqued","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.058_b0065","unstructured":"Shingrix (zoster vaccine recombinant, ajuvanted). Highlights of prescribing information. http:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm581605.pdf. [last accessed November 7, 2019]."},{"key":"10.1016\/j.vaccine.2019.11.058_b0070","unstructured":"Medical Dictionary for Regulatory Activities Terminology (MedDRA), 21.0. http:\/\/www.meddra.org\/ [last accessed November 7, 2019]."},{"key":"10.1016\/j.vaccine.2019.11.058_b0075","unstructured":"International Conference on Harmonisation, Topic E2A: Clinical safety data management: Definitions and standards for expedited reporting. http:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-15.pdf. [last accessed November 7, 2019]."},{"key":"10.1016\/j.vaccine.2019.11.058_b0080","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s40264-014-0237-9","article-title":"Use of logistic regression to combine two causality criteria for signal detection in vaccine spontaneous report data","volume":"37","author":"Van Holle","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2019.11.058_b0085","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/pds.3226","article-title":"Using time-to-onset for detecting safety signals in spontaneous reports of adverse events following immunization: a proof of concept study","volume":"21","author":"Van Holle","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2019.11.058_b0090","unstructured":"Practical aspects of signal detection in pharmacovigilance. Report of CIOMS Working Group VIII. Council for International Organizations of Medical Sciences, Geneva; 2010."},{"key":"10.1016\/j.vaccine.2019.11.058_b0095","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.vaccine.2013.01.042","article-title":"Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines","volume":"31","author":"Tavares Da Silva","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.058_b0100","unstructured":"Kohl KS, Bonhoeffer J, Braun MM, Chen RT, Duclos P, Heijbel H, et al. The Brighton Collaboration: Creating a global standard for case definitions (and guidelines) for adverse events following immunization. In: Henriksen K, Battles JB, Marks ES, Lewin DI, editors. Advances in patient safety: from research to implementation (Volume 2: Concepts and Methodology). Rockville MD; 2005."},{"key":"10.1016\/j.vaccine.2019.11.058_b0105","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how\u2019s and what\u2019s of vaccine reactogenicity","volume":"4","author":"Herv\u00e9","year":"2019","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2019.11.058_b0110","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/pds.3918","article-title":"Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines","volume":"25","author":"Mahaux","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2019.11.058_b0115","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(09)61877-8","article-title":"Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines","volume":"374","author":"Black","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.11.058_b0120","unstructured":"Centers for Disease Control and Prevention, National Center for Health Statistics: (NCHS) Multiple cause of death data. Underlying cause of death 1999-2016 on CDC WONDER online database. http:\/\/wonder.cdc.gov\/ [last accessed June 25, 2019]."},{"key":"10.1016\/j.vaccine.2019.11.058_b0125","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000109501","article-title":"Hospital admissions for Guillain-Barre syndrome in the United States, 1993\u20132004","volume":"29","author":"Frenzen","year":"2007","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.vaccine.2019.11.058_b0130","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/jnnp.2007.118810","article-title":"Incidence of Guillain-Barre syndrome in Alberta, Canada: an administrative data study","volume":"79","author":"Hauck","year":"2008","journal-title":"J Neurol Neurosurg Psych"},{"key":"10.1016\/j.vaccine.2019.11.058_b0135","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000369344","article-title":"Estimation of background incidence rates of Guillain-Barre syndrome in Germany \u2013 a retrospective cohort study with electronic healthcare data","volume":"43","author":"Hense","year":"2014","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.vaccine.2019.11.058_b0140","unstructured":"The Federal Health Monitoring System. Deaths, cases per 100,000 inhabitants (age-standardized) (from 1998). http:\/\/www.gbe-bund.de\/oowa921-install\/servlet\/oowa\/aw92\/dboowasys921.xwdevkit\/xwd_init?gbe.isgbetol\/xs_start_neu\/&p_aid=3&p_aid=43292617&nummer=6&p_sprache=E&p_indsp=-&p_aid=88844908 [last accessed June 25, 2019]."},{"key":"10.1016\/j.vaccine.2019.11.058_b0145","unstructured":"Statistics Canada. Table 13-10-0710-01. Deaths and mortality rates, by age group. http:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1310071001 [last accessed June 25, 2019]."},{"key":"10.1016\/j.vaccine.2019.11.058_b0150","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.058_b0155","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1177\/014107687907200908","article-title":"Guillain-Barre syndrome: the swine influenza virus vaccine incident in the United States of America, 1976\u201377: preliminary communication","volume":"72","author":"Langmuir","year":"1979","journal-title":"J R Soc Med"},{"key":"10.1016\/j.vaccine.2019.11.058_b0160","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976\u20131977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.11.058_b0165","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.vaccine.2016.05.023","article-title":"Facial nerve palsy including Bell's palsy: case definitions and guidelines for collection, analysis, and presentation of immunisation safety data","volume":"35","author":"Rath","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.058_b0170","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"Ruggeberg","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.058_b0175","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1053\/spid.2002.125864","article-title":"The science of evaluation of adverse events associated with vaccination","volume":"13","author":"Halsey","year":"2002","journal-title":"Semin Pediatr Infect Dis"},{"issue":"Suppl C","key":"10.1016\/j.vaccine.2019.11.058_b0180","doi-asserted-by":"crossref","first-page":"C40","DOI":"10.1016\/S0149-2918(98)80007-6","article-title":"Limitations and strengths of spontaneous reports data","volume":"20","author":"Goldman","year":"1998","journal-title":"Clin Ther"},{"key":"10.1016\/j.vaccine.2019.11.058_b0185","article-title":"The impact of reactogenicity after the first dose of recombinant zoster vaccine upon the physical functioning and quality of life of older adults: an open phase III trial","author":"Schmader","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.vaccine.2019.11.058_b0190","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.4049\/jimmunol.1400948","article-title":"Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells","volume":"193","author":"Didierlaurent","year":"2014","journal-title":"J Immunol"},{"issue":"Suppl 10","key":"10.1016\/j.vaccine.2019.11.058_b0195","doi-asserted-by":"crossref","first-page":"K98","DOI":"10.1016\/j.vaccine.2013.04.088","article-title":"Post-licensure rapid immunization safety monitoring program (PRISM) data characterization","volume":"31","author":"Baker","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.058_b0200","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000438752","article-title":"A multicentric prospective incidence study of Guillain-Barre syndrome in Italy. The ITANG study","volume":"45","author":"Benedetti","year":"2015","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.vaccine.2019.11.058_b0205","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/jns.12202","article-title":"Guillain-Barre syndrome in France: a nationwide epidemiological analysis based on hospital discharge data (2008\u20132013)","volume":"22","author":"Delannoy","year":"2017","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.vaccine.2019.11.058_b0210","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pvr.2017.03.001","volume":"3","author":"Skufca","year":"2017","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.vaccine.2019.11.058_b0215","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1529-8027.2011.00356.x","article-title":"Guillain-Barre syndrome: background incidence rates in The Netherlands","volume":"16","author":"van der Maas","year":"2011","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.vaccine.2019.11.058_b0220","doi-asserted-by":"crossref","first-page":"91","DOI":"10.15585\/mmwr.mm6804a4","article-title":"Postlicensure safety surveillance of recombinant zoster vaccine (Shingrix) - United States, October 2017-June 2018","volume":"68","author":"Hesse","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2019.11.058_b0225","unstructured":"Shimabukuro T. February 2019 Advisory Committee on Immunization Practices (ACIP) meeting. Update on post-licensure safety monitoring of recombinant zoster vaccine (RZV, Shingrix). http:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2019-02\/Zoster-2-Shimabukuro-508.pdf [last accessed June 25, 2019]."},{"key":"10.1016\/j.vaccine.2019.11.058_b0230","unstructured":"Shimabukuro T. Update on post-licensure safety monitoring of recombinant zoster vaccine (RZV, Shingrix). June 2019 Advisory Committee on Immunization Practices (ACIP) meeting. http:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2019-06\/Zoster-02-Shimabukuro-508.pdf [last accessed October 28, 2019]."},{"key":"10.1016\/j.vaccine.2019.11.058_b0235","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1016\/j.vaccine.2015.05.006","article-title":"Vaccination errors reported to the Vaccine Adverse Event Reporting System, (VAERS) United States, 2000\u20132013","volume":"33","author":"Hibbs","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.058_b0240","doi-asserted-by":"crossref","first-page":"161","DOI":"10.15585\/mmwr.mm6506a4","article-title":"Notes from the field: administration error involving a meningococcal conjugate vaccine - United States, March 1, 2010-September 22, 2015","volume":"65","author":"Su","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2019.11.058_b0245","unstructured":"Zostavax (Zoster Vaccine Live). Highlights of prescribing information. http:\/\/www.fda.gov\/media\/119879\/download [last accessed April 2, 2019]."},{"key":"10.1016\/j.vaccine.2019.11.058_b0250","doi-asserted-by":"crossref","first-page":"585","DOI":"10.15585\/mmwr.mm6720a4","article-title":"Notes from the field: Vaccine administration errors involving recombinant zoster vaccine - United States, 2017\u20132018","volume":"67","author":"Shimabukuro","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2019.11.058_b0255","unstructured":"Centers for Disease Control and Prevention. New shingles vaccines fact sheet for healthcare providers-Protect your patients with new shingles vaccine. http:\/\/www.cdc.gov\/shingles\/downloads\/shingles-factsheet-hcp.pdf [last accessed June 25, 2019]."},{"key":"10.1016\/j.vaccine.2019.11.058_b0260","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2019.11.058_b0265","unstructured":"Shingrix (Herpes zoster vaccine (non-live recombinant, AS01B adjuvanted) [Facebook page, only accessible from Canada]. http:\/\/www.facebook.com\/SHINGRIXca [last accessed May 27, 2019]."},{"key":"10.1016\/j.vaccine.2019.11.058_b0270","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1016\/j.vaccine.2007.04.060","article-title":"Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"25","author":"Sejvar","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.058_b0275","doi-asserted-by":"crossref","first-page":"6572","DOI":"10.1016\/j.vaccine.2016.09.031","article-title":"Systemic lupus erythematosus: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"34","author":"Hersh","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.058_b0280","doi-asserted-by":"crossref","first-page":"6561","DOI":"10.1016\/j.vaccine.2016.09.032","article-title":"Single organ cutaneous vasculitis: case definition & guidelines for data collection, analysis, and presentation of immunization safety data","volume":"34","author":"Zanoni","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.058_b0285","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.vaccine.2016.09.024","article-title":"IgA vasculitis (Henoch-Schonlein): case definition andguidelines for data collection, analysis, and presentation of immunisation safety data","volume":"35","author":"Woerner","year":"2017","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:42:45Z","timestamp":1759401765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19316007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":57,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0264410X19316007"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.11.058","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.11.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}